Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new strain of coronavirus and the causative agent of the current global pandemic of coronavirus disease 2019 (COVID-19). There are currently no FDA-approved antiviral drugs for COVID-19 and there is an urgent need to develop treatment...
Main Authors: | Sangiliyandi Gurunathan, Min Hee Kang, Jin-Hoi Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.716407/full |
Similar Items
-
Exosome therapeutics for COVID‐19 and respiratory viruses
by: Kristen D. Popowski, et al.
Published: (2021-06-01) -
COVID-19: Characteristics and Therapeutics
by: Rameswari Chilamakuri, et al.
Published: (2021-01-01) -
Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease
by: M. Nazmul Hoque, et al.
Published: (2020-09-01) -
Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients
by: Sara Al-Khawaga, et al.
Published: (2020-10-01) -
Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes
by: Sangiliyandi Gurunathan, et al.
Published: (2019-04-01)